Loading...
•
Jun 30, 2022
Prothena Q2 2022 Earnings Report
Reported financial results and business highlights for the second quarter and first six months of 2022.
Key Takeaways
Prothena reported a net loss of $41.2 million for the second quarter of 2022, compared to a net income of $27.6 million for the same period in 2021. Total revenue for the quarter was $1.3 million, primarily from collaboration revenue from BMS, as compared to $60.1 million for the second quarter of 2021. The company's cash and restricted cash position was $510.1 million as of June 30, 2022.
Net cash used in operating and investing activities was $35.5 million in the second quarter of 2022.
Quarter-end cash and restricted cash position was $510.1 million.
FDA Fast Track designation granted in April for PRX012.
Topline data expected by year-end from Phase 1 clinical study of PRX005.
Prothena
Prothena
Prothena Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
The Company continues to expect the full year 2022 net cash used in operating and investing activities to be $120 to $132 million, which includes an expected $40 million clinical milestone payment from Novo Nordisk and expects to end the year with approximately $454 million in cash, cash equivalents and restricted cash (midpoint).